RNS Number : 4017O
Medicsight Plc
06 March 2009
Medicsight PLC
('Medicsight' or 'the Company')
Medicsight unveils new version of ColonCAD™ at ECR 2009
Medicsight PLC (AIM:MDST), industry leader in the development of Computer-Aided Detection (CAD) and image analysis software which assists in the early detection and diagnosis of disease, is pleased to announce it has launched ColonCAD API 4.0, the latest version of its computer-aided detection software, today at the European Congress of Radiology (ECR 2009) show in Vienna. The software is designed to assist radiologists in the detection of colorectal polyps in CT colonography image data. Version 4.0 includes a significant increase in the performance of the polyp detection algorithm, reducing the number of false positive CAD marks displayed for each patient case.
Dr David Burling, Consultant Gastrointestinal Radiologist and VC Program Director at St. Mark's Hospital, London, UK commented today 'We welcome this latest improvement to Medicsight's ColonCAD product. CAD is now an integral part of our reading strategy in routine clinical practice. It improves interpretation accuracy and is complimentary to workflow'.
Internal testing on a dataset of 91 patient cases showed that the ColonCAD API 4.0 maintains the same high levels of sensitivity to the previous version but displays a 50% reduction in false positives, with the CAD now returning a mean of 6.5 false positive marks per patient case *. ColonCAD API 4.0 demonstrates the following sensitivity:
|
Size of Polyp
|
Sensitivity
|
|
2mm-50mm
|
85%
|
|
6mm-9mm
|
90%
|
|
10mm+ (clinically significant)
|
92%+
|
The patient data used in this testing remained independent from the development of the CAD and have been endoscopically validated and reviewed by a panel of expert radiologists to determine the ground truth against which the CAD performance was assessed.
Allan Rowley, Chief Executive of Medicsight, commented 'Previous research has shown Medicsight's ColonCAD significantly improves the performance of radiologists in the detection of polyps in CT colonography image data. The reduction in the numbers of false positives returned by our latest version of CAD is expected to further improve the performance of radiologists, by reducing the number of CAD marks which must be assessed when reviewing a patient dataset.'
ColonCAD API 4.0 has been CE Marked and will be available for sale in Europe through Medicsight's network of partners.
More than 17,000 medical and industry professionals from over 95 countries will be attending this year's ECR which is taking place in the Austria Center, Vienna from 6-10 March. Visitors will be able to see demonstrations of the Medicsight ColonCAD software integrated into their partners' 3D advanced visualisation workstations at the company's exhibition booth no 506 in Expo E.
* Data on file, Medicsight PLC
- ENDS -
For further information:
|
Medicsight PLC
|
www.medicsight.com
|
|
Allan Rowley
|
+44 (0)20 7605 7950
|
|
Nomura Code
|
|
|
Juliet Thompson
Jonathan Senior
|
+44 (0) 20 7776 1204
+44 (0) 20 7776 1219
|
Media enquiries:
Notes to editors
Medicsight PLC is a UK-headquartered, research driven, leading developer of computer-aided detection (CAD) and image analysis software for the medical imaging market. The CAD software automatically highlights suspicious areas on computerised tomography (CT) scans of the colon and lung, helping radiologists to identify, measure and analyse potential disease and early indicators of disease. Medicsight's CAD software has been validated using one of the world's largest and most population diverse databases of verified patient CT scan data. Medicsight's ColonCAD™ and LungCAD™ software products are seamlessly integrated with the advanced 3D visualisation workstations of several industry-leading imaging equipment partners.
About Computer-Aided Detection
With increasingly sophisticated radiological imaging hardware such as Multi-Detector CT scanners, radiologists are facing a growing challenge in the amount of detailed patient image data that they must review for each patient examination. Some CT scan examinations generate as many as 2000 images per patient. Review of this data by the radiologist is not only time-consuming but also prone to error due to reader fatigue. CAD software can help the reviewing radiologist by analysing the image data and automatically highlighting suspicious regions of interest for closer inspection. Without CAD software some potential abnormalities or areas of disease may be overlooked. This can be critical for diagnosis and the management of patient outcomes as early detection of disease greatly increases the probability of successful treatment and a positive therapeutic outcome. In addition to supporting individual radiologists CAD also has the potential to help standardise CT interpretation across both individuals and institutions thereby supporting population based screening programmes.
About Medicsight's CAD software
Medicsight's ColonCAD™ and LungCAD™ software use an advanced CAD algorithm to analyse CT scans of the colon and lung and automatically highlight suspicious areas that may be indicators of disease. CAD may highlight areas easily overlooked by the reviewing radiologist, such as small lesions or regions that are hidden from view behind folds in the colon or normal structures and surrounding tissue in the lung.
Both CAD products seamlessly integrate with the advanced 3D visualisation platforms of industry-leading imaging equipment partners. The integrated systems provide sophisticated image viewing capabilities, including 3D reconstructed image data, with the added advantage of demonstrating automatic CAD findings to assist clinical end users in the detection and analysis of disease. This allows clinical end users to perform either a 'second read', where CAD findings are displayed to the user after completion of an initial review of the CT scan data, or a 'concurrent read' where CAD findings are displayed during the user's initial review of the original CT scan images.
Since inception, Medicsight has developed close and lasting relationships with some of the world's foremost clinicians in product related areas. This provides the Company with a wealth of clinical expertise and dedicated clinical research to support ongoing product development. Medicsight also collaborates with a number of leading academic institutions and clinical research programmes worldwide to develop the Company's comprehensive database of population diverse verified patient CT scan data, thus allowing Medicsight's products to be validated to the highest possible standards.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAILFSEVIIEIIA